Citations

Clear

6273 citation(s) found for "To, Andrew".

Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR®
Fazel, Reza , Curtis, Jeptha P. , Wang, Yongfei , Tsai, Thomas T., Chen, Jersey , Shah, Nilay D. , Nallamothu, Brahmajee K. , Einstein, Andrew Jeffrey , Smith‐Bindman, Rebecca , Krumholz, Harlan M.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 22, 2013 | Volume: 82 | Issue: 7 | Pages: 1091-1105

10.1002/ccd.24996 | PMID 23703793 Get It

ABSTRACTObjectivesIdentifying the distributions and determinants of fluoroscopy time for invasive coronary angiography (ICA) and percutaneous coronary intervention (PCI).BackgroundICA and PCI are significant contributors to radiation exposure from medical imaging in the US. Fluoroscopy time is a potentially modifiable determinant of radiation exposure for these procedures, but has not been well characterized in contemporary practice.MethodsWe evaluated the distribution of fluoroscopy time in patients undergoing ICA and/or PCI in the CathPCI Registry®, stratifying patients by numerous clinical scenarios. Hierarchical models were used to determine patient, procedure, operator and hospital‐level factors associated with fluoroscopy time for these procedures.ResultsOur study included a total of 3,295,348 ICA and PCI procedures performed by 9,600 operators from January 2005 through June 2009. There was wide variation in fluoroscopy times for these procedures with median [IQR] fluoroscopy times of 2.6 [1.7–4.5] minutes for ICA, 6.7 [4.2–10.8] minutes for ICA in patients with prior coronary artery bypass grafting (CABG), 10.1 [6.0–17.4] minutes for PCI, 10.7 [7.0–16.9] minutes for PCI with ICA, and 16.0 [10.6–24.0] minutes for PCI and ICA in patients with prior CABG. Prolonged fluoroscopy times (>30 minutes) were rare for ICA, but occurred in 6.7% of PCIs and 14.7% of PCIs in patients with prior CABG. After accounting for patient characteristics and procedure complexity, operator and hospital‐level factors explained nearly 20% of the variation in fluoroscopy time.ConclusionsFluoroscopy times vary widely during ICA and PCI with operator and hospital‐level factors contributing substantially to these differences. A better understanding of potentially modifiable sources of this variation will elucidate opportunities for enhancing the radiation safety of these procedures. © 2013 Wiley Periodicals, Inc.
Attributes Associated with Patient Perceived Outcome in an Academic Chronic Pain Clinic
Trentman, Terrence L. , Chien, James J., Rosenfeld, David M. , Gorlin, Andrew , Seamans, David P. , Freeman, John A., Wilshusen, Laurie , Chang, Yu‐Hui

Mayo Clinic

Pain Practice | May 22, 2013 | Volume: 14 | Issue: 3 | Pages: 217-222

10.1111/papr.12077 | PMID 23692280 Get It

AbstractObjectivesPatient satisfaction is tied to outcome, but there is scant literature on the relationship of patient perceived outcome and attributes of the pain clinic visit, including the patient interaction with the pain management specialist. The primary purpose of this study is to identify attributes of the patient–provider interaction most strongly associated with patient perceived outcome of their clinic visit. The secondary aim is to correlate patient perceived outcome with patient self‐rated overall health.MethodsA patient satisfaction survey conducted via phone approximately 3 weeks after the patient's pain clinic visit.ResultsThe response rate was 60.2%; 987 patient surveys collected between 2006 and 2010 were used in the analysis. Four factors were significantly associated with the outcome: (1) Explanations by the physician of the patient's condition and treatment, (2) clear instructions regarding post‐appointment activities, (3) knowing the patient as a person, and (4) the patient's self‐rated health. In terms of the secondary objective, those who answered very good/excellent regarding their self‐rated health had an 87% increased odds of better (very good/excellent) outcome of their pain clinic visit (or 1.87 times the odds of better outcome) compared with those who answered poor/fair/good.ConclusionsOur results suggest that pain physicians may positively impact patient perceived outcomes of clinic visits by explaining the patient's condition and treatment, providing instructions, and taking the time to understand the patient and their values.
Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation
Lueder, Thomas G. von , Sangaralingham, S. Jeson , Wang, Bing H. , Kompa, Andrew R. , Burnett, John C. , Krum, Henry, Sangaralingham, S. Jeson , Atar, Dan

Mayo Clinic

Circulation: Heart Failure | May 21, 2013 | Volume: 6 | Issue: 3 | Pages: 594-605

10.1161/circheartfailure.112.000289 | PMID 23694773 Get It

Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial α5 Integrin
Cao, Ying , Hoeppner, Luke H. , Bach, Steven , Guangqi, E, Wang, Enfeng , Wu, Jianmin , Cowley, Mark J. , Chang, David K. , Waddell, Nicola , Grimmond, Sean M. , Biankin, Andrew V. , Daly, Roger J. , Zhang, Xiao Hui , E, Guangqi, Guo, Yan , Mukhopadhyay, Debabrata , Waddell, Nicola , Chang, David , Grimmond, Sean M , Biankin, Andrew V

Mayo Clinic

Cancer Research | May 21, 2013 | Volume: 73 | Issue: 14 | Pages: 4579-4590

10.1158/0008-5472.can-13-0529 | PMID 23689123 Get It

Abstract Metastasis, the leading cause of cancer death, requires tumor cell intravasation, migration through the bloodstream, arrest within capillaries, and extravasation to invade distant tissues. Few mechanistic details have been reported thus far regarding the extravasation process or re-entry of circulating tumor cells at metastatic sites. Here, we show that neuropilin-2 (NRP-2), a multifunctional nonkinase receptor for semaphorins, vascular endothelial growth factor (VEGF), and other growth factors, expressed on cancer cells interacts with α5 integrin on endothelial cells to mediate vascular extravasation and metastasis in zebrafish and murine xenograft models of clear cell renal cell carcinoma (RCC) and pancreatic adenocarcinoma. In tissue from patients with RCC, NRP-2 expression is positively correlated with tumor grade and is highest in metastatic tumors. In a prospectively acquired cohort of patients with pancreatic cancer, high NRP-2 expression cosegregated with poor prognosis. Through biochemical approaches as well as Atomic Force Microscopy (AFM), we describe a unique mechanism through which NRP-2 expressed on cancer cells interacts with α5 integrin on endothelial cells to mediate vascular adhesion and extravasation. Taken together, our studies reveal a clinically significant role of NRP-2 in cancer cell extravasation and promotion of metastasis. Cancer Res; 73(14); 4579–90. ©2013 AACR.
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Terpos, Evangelos , Morgan, Gareth J. , Dimopoulos, Meletios Α. , Lentzsch, Suzanne , Sezer, Orhan , García‐Sánz, Ramón , Shimizu, Kazuyuki , Turesson, Ingemar , Reiman, Tony , Merlini, Giampaolo , Spencer, Andrew , Leleu, Xavier , Cavo, Michèle , Munshi, Nikhil C. , Durie, Brian G.M. , Roodman, G. David, Drake, Matthew T. , Raje, Noopur , Jurczyszyn, Artur , Rajkumar, S. Vincent , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Garcia-Sanz, Ramon , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | May 21, 2013 | Volume: 31 | Issue: 18 | Pages: 2347-2357

10.1200/jco.2012.47.7901 | PMID 23690408 Get It

Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) –related bone disease. Methodology An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Recommendations Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
Overall survival advantage with partial nephrectomy: A bias of observational data?
Shuch, Brian , Lai, Julie , Vourganti, Srinivas , Kim, Simon P. , Dick, Andrew W., Chow, Wong‐Ho , Saigal, Chris, Project, the Urologic Diseases in America, Hanley, Janet M. , Setodji, Claude Messan , Project, the Urologic Diseases in America

Mayo Clinic

Cancer | May 14, 2013 | Volume: 119 | Issue: 16 | Pages: 2981-2989

10.1002/cncr.28141 | PMID 23674264 Get It

BACKGROUNDPartial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.METHODSA matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare dataset. Individuals treated with PN or RN for localized renal cell carcinoma (RCC) measuring ≤4 cm were compared with 2 control groups (non–muscle‐invasive bladder cancer (BCC) and noncancer controls (NCC). Using a greedy algorithm, RCC groups were matched with controls by demographics and comorbidities. OS for surgical groups and controls were compared. The cause of death was evaluated for cancer groups when differences in OS were noted.RESULTSPatients undergoing PN and RN were matched with controls. All cancer groups had >95% 10‐year cancer‐specific survival (CSS). Median OS was similar between RN (9.05 years) and BCC (8.67 years; P = .067) and NCC (8.77 years; P = .49). Median OS was improved for PN (10.45 years) compared with BCC (8.75 years; P<.001) and NCC controls (8.76 years; P<.001). A multivariate Cox hazards model demonstrated that PN improved OS compared with NCC (hazard ratio, 1.257; P<.001) and BCC (hazard ratio, 1.364; P<.001).CONCLUSIONSRN patients had similar OS compared with controls, suggesting that this treatment modality does not compromise survival. Patients undergoing PN had improved OS compared with controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER‐Medicare case series is likely the result of selection bias involving unmeasured confounders. Cancer 2013;119:2981—2989. © 2013 American Cancer Society.
Reply to K. Orendi et al
Mrózek, Krzysztof , Maharry, Kati , Carroll, Andrew J. , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra

Mayo Clinic

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 18 | Pages: 2361-2362

10.1200/jco.2013.49.2504 | PMID 23930275 Get It

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Marcucci, Guido , Maharry, Kati , Metzeler, Klaus H. , Wu, Yue-Zhong, Mrózek, Krzysztof , Kohlschmidt, Jessica, Whitman, Susan P., Schwind, Sebastian , Becker, Heiko , Eisfeld, Ann‐Kathrin , Carroll, Andrew J. , Powell, Bayard L., Kolitz, Jonathan E. , Garzon, Ramiro , Stone, Richard M. , Bloomfield, Clara D. , Volinia, Stefano , Nicolet, Deedra , Mendler, Jason H. , Caligiuri, Michael A.

Mayo Clinic

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 17 | Pages: 2086-2093

10.1200/jco.2012.45.6228 | PMID 23650424 Get It

Purpose To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.
The New Mayo Clinic Equation for Estimating Glomerular Filtration Rate
Cosio, Fernando G., Rule, Andrew D.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 142 | Issue: 8 | Pages: 681

10.7326/0003-4819-142-8-200504190-00031 Get It

Reviews, Notes, and Listings: Pulmonary Medicine: Pulmonary Complications of Systemic Disease
Limper, Andrew H.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 119 | Issue: 4 | Pages: 352

10.7326/0003-4819-119-4-199308150-00046 Get It